Triple negative breast cancer: Is chemotherapy always necessary?
Association of Breast Surgery ePoster Library. Halkias C. 05/15/17; 166264; P021
C. Halkias
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction:
Triple negative tumors have poor prognosis. Two previous studies from our institution have shown conflicting results; the first recommended chemotherapy in all cases, and a subsequent study indicated it was safe to omit chemotherapy in node negative cases. This study provides an updated analysis of our patient population.
Methods:
Triple negative breast cancer patient diagnosed between 2008 and 2015 at Conquest and Eastbourne hospitals were included. Statistical analysis was performed on SPSS 22.
Results:
105 patients included with a mean age of 67.6 years. 82 (78.1%) patients had grade III disease. Mean tumour size was 30mm and 38 patients (36.2%) were node-positive. 104 patients had surgery, and 67 (64.4%) underwent axillary clearance. 70 patients (66.67%) received adjuvant chemotherapy and 79 (75.2%) radiotherapy. At mean follow-up of 38 months, 11 (10.5%) patients had local recurrence, 15 (14.3%) distant metastases and 20 (19%) were deceased. There were only 2 deaths (8.3%) amongst 24 node negative patients who did not receive chemotherapy. Of the 70 patients who had chemotherapy 19 (27.1%) had disease relapse. Tumor size (P = 0.010) and Grade (P = 0.039) were the only statistically significant factors affecting survival. In 64 patients with node negative disease, multivariate analysis (OR 0.2, P=0.630) and univariate analysis (OR = 1.33, P= 0.672) showed no statistically significant difference between chemotherapy or no chemotherapy in terms of overall survival.
Conclusions
Longer follow-up is required in both groups, but patients with larger tumours and high grade seem to benefit from chemotherapy irrespective of nodal status.
Triple negative tumors have poor prognosis. Two previous studies from our institution have shown conflicting results; the first recommended chemotherapy in all cases, and a subsequent study indicated it was safe to omit chemotherapy in node negative cases. This study provides an updated analysis of our patient population.
Methods:
Triple negative breast cancer patient diagnosed between 2008 and 2015 at Conquest and Eastbourne hospitals were included. Statistical analysis was performed on SPSS 22.
Results:
105 patients included with a mean age of 67.6 years. 82 (78.1%) patients had grade III disease. Mean tumour size was 30mm and 38 patients (36.2%) were node-positive. 104 patients had surgery, and 67 (64.4%) underwent axillary clearance. 70 patients (66.67%) received adjuvant chemotherapy and 79 (75.2%) radiotherapy. At mean follow-up of 38 months, 11 (10.5%) patients had local recurrence, 15 (14.3%) distant metastases and 20 (19%) were deceased. There were only 2 deaths (8.3%) amongst 24 node negative patients who did not receive chemotherapy. Of the 70 patients who had chemotherapy 19 (27.1%) had disease relapse. Tumor size (P = 0.010) and Grade (P = 0.039) were the only statistically significant factors affecting survival. In 64 patients with node negative disease, multivariate analysis (OR 0.2, P=0.630) and univariate analysis (OR = 1.33, P= 0.672) showed no statistically significant difference between chemotherapy or no chemotherapy in terms of overall survival.
Conclusions
Longer follow-up is required in both groups, but patients with larger tumours and high grade seem to benefit from chemotherapy irrespective of nodal status.
Introduction:
Triple negative tumors have poor prognosis. Two previous studies from our institution have shown conflicting results; the first recommended chemotherapy in all cases, and a subsequent study indicated it was safe to omit chemotherapy in node negative cases. This study provides an updated analysis of our patient population.
Methods:
Triple negative breast cancer patient diagnosed between 2008 and 2015 at Conquest and Eastbourne hospitals were included. Statistical analysis was performed on SPSS 22.
Results:
105 patients included with a mean age of 67.6 years. 82 (78.1%) patients had grade III disease. Mean tumour size was 30mm and 38 patients (36.2%) were node-positive. 104 patients had surgery, and 67 (64.4%) underwent axillary clearance. 70 patients (66.67%) received adjuvant chemotherapy and 79 (75.2%) radiotherapy. At mean follow-up of 38 months, 11 (10.5%) patients had local recurrence, 15 (14.3%) distant metastases and 20 (19%) were deceased. There were only 2 deaths (8.3%) amongst 24 node negative patients who did not receive chemotherapy. Of the 70 patients who had chemotherapy 19 (27.1%) had disease relapse. Tumor size (P = 0.010) and Grade (P = 0.039) were the only statistically significant factors affecting survival. In 64 patients with node negative disease, multivariate analysis (OR 0.2, P=0.630) and univariate analysis (OR = 1.33, P= 0.672) showed no statistically significant difference between chemotherapy or no chemotherapy in terms of overall survival.
Conclusions
Longer follow-up is required in both groups, but patients with larger tumours and high grade seem to benefit from chemotherapy irrespective of nodal status.
Triple negative tumors have poor prognosis. Two previous studies from our institution have shown conflicting results; the first recommended chemotherapy in all cases, and a subsequent study indicated it was safe to omit chemotherapy in node negative cases. This study provides an updated analysis of our patient population.
Methods:
Triple negative breast cancer patient diagnosed between 2008 and 2015 at Conquest and Eastbourne hospitals were included. Statistical analysis was performed on SPSS 22.
Results:
105 patients included with a mean age of 67.6 years. 82 (78.1%) patients had grade III disease. Mean tumour size was 30mm and 38 patients (36.2%) were node-positive. 104 patients had surgery, and 67 (64.4%) underwent axillary clearance. 70 patients (66.67%) received adjuvant chemotherapy and 79 (75.2%) radiotherapy. At mean follow-up of 38 months, 11 (10.5%) patients had local recurrence, 15 (14.3%) distant metastases and 20 (19%) were deceased. There were only 2 deaths (8.3%) amongst 24 node negative patients who did not receive chemotherapy. Of the 70 patients who had chemotherapy 19 (27.1%) had disease relapse. Tumor size (P = 0.010) and Grade (P = 0.039) were the only statistically significant factors affecting survival. In 64 patients with node negative disease, multivariate analysis (OR 0.2, P=0.630) and univariate analysis (OR = 1.33, P= 0.672) showed no statistically significant difference between chemotherapy or no chemotherapy in terms of overall survival.
Conclusions
Longer follow-up is required in both groups, but patients with larger tumours and high grade seem to benefit from chemotherapy irrespective of nodal status.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}